Supriya Lifescience share price
NSE: SUPRIYABSE: 543434Pharmaceuticals & BiotechnologySmall Cap
Supriya Lifescience Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2021 · Issue price ₹274
Last close ₹847.30down ₹22.00 (2.53%)BSE ₹846.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹869.30.
30 Oct: open ₹869.30, high ₹880.45, low ₹841.80
52-week range of traded prices to 30 Oct 2026
₹545.50Low, 24 Mar 2026₹1,085.00High, 1 Jun 2026
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,819 Cr733rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.38
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.69
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 92,05249.3% delivered
About Supriya Lifescience
Supriya Lifescience Limited develops and makes niche active pharmaceutical ingredients (APIs, the active substances in medicines), finished formulations and contract manufacturing services for drug companies worldwide.1 It is headquartered in Mumbai and manufactures at Lote Parshuram in Ratnagiri and at Ambernath in Thane, Maharashtra.234
Its APIs span anaesthetics, antihistamines, analgesics, vitamins, anti-asthmatics and anti-allergics, and include brompheniramine maleate, mepyramine maleate and ketamine hydrochloride.56 Its Lote plant has approvals from the US Food and Drug Administration (USFDA), European regulators and Health Canada, and the company holds more than 50 registrations across global markets, including 21 US drug master files (dossiers on how a drug is made, filed with the US regulator).78 In 2026, it commercialised a contract manufacturing (CMO) facility at Ambernath.9 It began in 1987 as a partnership firm and was incorporated as a public limited company in 2008.10 Its shares are listed on the BSE and NSE.11
The company has no subsidiary, joint venture or associate company.12 It is led by the Wagh family: chairman and executive director Satish Waman Wagh and his daughters Saloni Satish Wagh, managing director, and Shivani Satish Wagh, joint managing director.131415
Supriya Lifescience key points
Results
- In the year to Mar 2026, revenue from operations was ₹827.9 crore, up 18.9% on the year before, and profit after tax was ₹209.1 crore, up 11.2%.16
- In the quarter to Jun 2026, revenue from operations was ₹190 crore against ₹145 crore a year earlier, up 31%.17
- EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹47 crore against ₹52 crore a year earlier, and profit after tax was ₹24 crore against ₹35 crore, in the quarter to Jun 2026.18
- In the quarter to Jun 2026, the company said water shortages deferred sales of around ₹35 crore and a change in Maharashtra's solar power policy cut EBITDA by ₹8 crore.19
Revenue mix
- Amounts the company reports for these product groups (not its full revenue)2021The company describes anaesthetics, which are not in this list, as its largest therapeutic category.
Item year to Mar 2026 Vitamins ₹98.52 crore Anti-histamine ₹76.13 crore Anti-asthmatic ₹46.15 crore Anti-allergic ₹29.12 crore Analgesic ₹28.14 crore - Backward-integrated products (whose key inputs the company makes itself) were 76% of revenue in the year to Mar 2026; on its call of 14 Aug 2026, the company said 72% of total revenues were currently fully integrated.2223
Where revenue comes from
- In the year to Mar 2026, exports were 82% of revenue and Europe was the largest market at 40% of revenue.24
- In the quarter to Jun 2026, exports were 81% of revenue. Within exports, Asia contributed 39% of export revenue, Europe 35% and Latin America (LATAM) 20%.25
- The 10 largest customers contributed 52% of revenue in the year to Mar 2026.26
- The company serves more than 1,500 customers in over 120 countries.27
Plants and capacity
- In 2025, a new Module E production block at Lote Parshuram raised installed capacity from 597 KLPD to 932 KLPD (KLPD: kilolitres of reactor capacity per day).2829
- In its presentation of 13 Aug 2026, the company said Ambernath's finished dosage form (FDF, ready-to-use medicine) facilities for tablets, capsules, liquids, nasal, inhalation and injections were commissioned and making validation batches for regulatory filings.30
- On its earnings call of 14 Aug 2026, the company said a European Union (EU) audit of the Ambernath plant was scheduled for the second half of November, and that the formulation business there would start giving revenue after the audit.3132
- Capital expenditure in the year to Mar 2026 was ₹152 crore, directed largely towards Ambernath.33
Research and development
- In the year to Mar 2026, the company said it developed and commercialised 4 new APIs (lisdexamfetamine dimesylate, ibuprofen picanol, sevoflurane and ATS-8) and developed 12 new formulations.34
- Around 30 finished dosage products are under development, and the company has developed a novel semaglutide tablet formulation (semaglutide is a diabetes medicine) and filed intellectual property around it.35
What the company expects
- On its earnings call of 14 Aug 2026, the company said it expects revenue of closer to ₹1,000 crore in the year to Mar 2027.3637
- On its earnings call of 14 Aug 2026, the company said it would grow at a compound annual growth rate (CAGR) of about 20% a year, and that it sees potential to grow beyond 20% over the next couple of years.3839
- On its earnings call of 14 Aug 2026, the company said it has received all necessary clearances for its Patalganga site, to be developed in phases, with around ₹200 crore earmarked for phase 1.40
- The company stated in its annual report for the year to Mar 2026 that a 10-year contract manufacturing (CMO) agreement with a European pharma company is projected to contribute ₹600 million every year from the year to Mar 2027.41
Recent events
- The USFDA inspected the Lote plant from 2 Feb 2026 to 6 Feb 2026, ending with 1 minor observation, which the company addressed, and a report marked Voluntary Action Indicated, which the company said signifies a successful completion of the inspection.42
- On 30 Dec 2025, India Ratings and Research (Ind-Ra), a credit rating agency, assigned the company's ₹1,140 crore of bank loan facilities a rating of IND A+ with a positive outlook (short-term rating IND A1).43
Litigation and regulatory matters
- As of its call of 14 Aug 2026, the company said a case over an export consignment of a psychotropic drug (one that acts on the mind) was before the High Court, with 1 person in judicial custody and the shipping bill under investigation.444546
- On its earnings call of 14 Aug 2026, the company described a 2-day technical lapse: the export authorisation for the consignment had expired before the shipping bill was raised, which it attributed to human oversight by its logistics department.47
Last updated
All 47 sources, each with its page
- 1. Annual report, 1 Sep 2026, page 5
- 2. Annual report, 1 Sep 2026, page 8
- 3. Annual report, 1 Sep 2026, page 17
- 4. Investor presentation, 13 Aug 2026, page 16
- 5. Annual report, 1 Sep 2026, page 5
- 6. Annual report, 1 Sep 2026, page 7
- 7. Annual report, 1 Sep 2026, page 38
- 8. Annual report, 1 Sep 2026, page 21
- 9. Annual report, 1 Sep 2026, page 7
- 10. Annual report, 1 Sep 2026, page 5
- 11. Annual report, 1 Sep 2026, page 7
- 12. Annual report, 1 Sep 2026, page 38
- 13. Annual report, 1 Sep 2026, page 27
- 14. Annual report, 1 Sep 2026, page 33
- 15. Annual report, 1 Sep 2026, page 34
- 16. Annual report, 1 Sep 2026, page 13
- 17. Earnings call, 14 Aug 2026, page 5
- 18. Earnings call, 14 Aug 2026, page 5
- 19. Earnings call, 14 Aug 2026, page 3
- 20. Annual report, 1 Sep 2026, page 36
- 21. Annual report, 1 Sep 2026, page 13
- 22. Annual report, 1 Sep 2026, page 13
- 23. Earnings call, 14 Aug 2026, page 4
- 24. Annual report, 1 Sep 2026, page 16
- 25. Earnings call, 14 Aug 2026, page 4
- 26. Annual report, 1 Sep 2026, page 8
- 27. Annual report, 1 Sep 2026, page 5
- 28. Annual report, 1 Sep 2026, page 7
- 29. Investor presentation, 13 Aug 2026, page 15
- 30. Investor presentation, 13 Aug 2026, page 16
- 31. Earnings call, 14 Aug 2026, page 6
- 32. Earnings call, 14 Aug 2026, page 13
- 33. Annual report, 1 Sep 2026, page 14
- 34. Annual report, 1 Sep 2026, page 18
- 35. Annual report, 1 Sep 2026, page 15
- 36. Earnings call, 14 Aug 2026, page 4
- 37. Earnings call, 14 Aug 2026, page 9
- 38. Earnings call, 14 Aug 2026, page 13
- 39. Earnings call, 14 Aug 2026, page 15
- 40. Earnings call, 14 Aug 2026, page 5
- 41. Annual report, 1 Sep 2026, page 36
- 42. Exchange filing, 22 Apr 2026, page 1
- 43. Exchange filing, 30 Dec 2025, page 1
- 44. Earnings call, 14 Aug 2026, page 8
- 45. Earnings call, 14 Aug 2026, page 9
- 46. Earnings call, 14 Aug 2026, page 13
- 47. Earnings call, 14 Aug 2026, page 9
Results
Standalone; ₹ crore.Supriya Lifescience quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +28.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +11.4%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹190 Crdown 31.38%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹24 Crdown 67.61%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 12.7%
Revenue by quarter
Peak revenue ₹277 Cr, quarter to Mar 2026; lowest ₹145 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 |
| Net profit | 46 | 47 | 50 | 35 | 50 | 50 | 74 | 24 |
| Net margin | 27.8% | 25.2% | 27.4% | 24.0% | 25.2% | 24.1% | 26.8% | 12.7% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹828 Crup 18.86%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹209 Crup 11.26%
- Net margin
- 25.3%
Revenue by year
Peak revenue ₹828 Cr, year to Mar 2026; lowest ₹461 Cr, year to Mar 2023
Net profit by year, a loss in red
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 530 | 461 | 570 | 696 | 828 |
| Net profit | 152 | 90 | 119 | 188 | 209 |
| Net margin | 28.6% | 19.5% | 20.9% | 27.0% | 25.3% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.Supriya Lifescience PE ratio and valuation
Price to earnings
At or below today's level on 84% of 976 trading days since Nov 2022.
LowestHighest
Its median28.90Industry median27.53
Price to book
At or below today's level on 75% of 1,101 trading days since May 2022.
LowestHighest
Its median4.71Industry median2.88
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 33% of 1,186 trading days since Dec 2021.
LowestHighest
Its median0.14%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −23.3% | +11.3% | −31.2% | 0.2% |
| 3 years | +43.5% | +32.5% | +8.2% | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
18 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 8 of the 9 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 18 funds holding Supriya Lifescience
- AddedAdded. Funds that held more shares than at the end of the month before.
- 5
- CutCut. Funds that held fewer shares than at the end of the month before.
- 4
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 8
| Fund | |||
|---|---|---|---|
 Abakkus Flexi Cap FundAbakkus Mutual Fund | 5,37,227 | 0.65% | ₹51.1 Cr |
 ITI Large & Midcap FundITI Mutual Fund | 1,15,795 | 1.59% | ₹11.0 Cr |
 Quantum Small Cap FundQuantum Mutual Fund | 1,09,252 | 3.97% | ₹10.4 Cr |
| ITI ELSS Tax Saver FundITI Mutual Fund | 91,519 | 1.96% | ₹8.70 Cr |
 Motilal Oswal Nifty Microcap 250 Index FundMotilal Oswal Mutual Fund | 69,241 | 0.27% | ₹6.58 Cr |
 WhiteOak Capital Pharma and Healthcare FundWhiteOak Capital Mutual Fund | 67,618 | 0.69% | ₹6.43 Cr |
| ITI Pharma and Healthcare FundITI Mutual Fund | 27,984 | 1.00% | ₹2.66 Cr |
| Quantum Flexi Cap FundQuantum Mutual Fund | 6,531 | 0.96% | ₹0.62 Cr |
| Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 718 | 0.15% | ₹0.07 Cr |
 Angel One Nifty Total Market Momentum Quality 50 Index FundAngel One Mutual Fund | 598 | 0.16% | ₹0.06 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Supriya Lifescience competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Supriya Lifescience in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Sanofi Consumer Healthcare IndiaSANOFICONR | 7,928 | 28.34 | 22.79 | +22.7% | +28.4% | 92.5% | 102.5% | 2.18% |
 Aarti PharmalabsAARTIPHARM | 7,914 | – | 3.51 | +13.4% | – | – | 11.9% | 0.40% |
 Sanofi IndiaSANOFI | 7,379 | 20.24 | 8.93 | −5.7% | +2.3% | 45.3% | 57.3% | 3.84% |
 Bliss GVS PharmaBLISSGVS | 6,885 | 42.71 | 5.34 | +24.9% | +47.0% | 13.3% | 14.9% | 0.23% |
 Morepen LaboratoriesMOREPENLAB | 6,211 | 32.94 | 4.50 | +30.2% | +91.2% | 14.6% | 14.3% | 0.18% |
 FDCFDC | 6,138 | 19.59 | 2.30 | +10.2% | +39.0% | 12.3% | 11.5% | 1.33% |
 Innova CaptabINNOVACAP | 5,867 | 37.54 | 5.43 | +34.5% | +20.4% | 15.3% | 15.0% | 0.20% |
 Sun Pharma Advanced Research CompanySPARC | 5,727 | 3.61 | 4.28 | +2,855.8% | – | 118.4% | 84.8% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Supriya Lifescience dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.00 a share, years to Mar 2025 and Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 4 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹1.00 |
| 4 Sep 2025 | Final | ₹1.00 |
| 20 Sep 2024 | Final | ₹0.80 |
| 15 Sep 2023 | Final | ₹0.60 |
| 1 Sep 2022 | Final | ₹0.60 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Supriya Lifescience announcements
Oct 2026
31 Oct · Analysts
30 Oct · Board meeting
19 Oct
13 Oct · General Updates
8 Oct
Sep 2026
Supriya Lifescience share price by year
Each calendar year to 2025.Supriya Lifescience share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 751.50 | +1.6% | 802.65 | 589.75 |
| 2024 | 739.80 | +135.0% | 806.85 | 295.75 |
| 2023 | 314.75 | +33.9% | 317.05 | 175.95 |
| 2022 | 235.05 | −51.4% | 570.30 | 223.30 |
| 2021 | 483.70 | – | 508.15 | 390.85 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2021 is from its first session, 28 Dec 2021.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 869.25 | 873.55 | 858.05 | 869.30 | 867.34 | 87,175 | 49.0% |
| 28 Oct 2026 | 853.00 | 879.20 | 840.70 | 862.25 | 861.12 | 1,99,541 | 38.1% |
| 27 Oct 2026 | 837.20 | 857.90 | 831.45 | 850.90 | 846.52 | 91,955 | 42.4% |
| 26 Oct 2026 | 815.00 | 839.25 | 807.15 | 833.05 | 827.48 | 90,442 | 32.1% |
| 23 Oct 2026 | 835.00 | 835.00 | 801.00 | 818.55 | 814.82 | 1,62,923 | 42.0% |
| 22 Oct 2026 | 837.00 | 852.25 | 825.20 | 836.25 | 838.85 | 1,12,881 | 43.0% |
| 21 Oct 2026 | 873.25 | 874.85 | 835.05 | 842.60 | 849.11 | 1,67,876 | 52.5% |
| 19 Oct 2026 | 889.10 | 904.90 | 867.70 | 873.25 | 887.64 | 1,99,658 | 38.0% |
| 16 Oct 2026 | 872.50 | 892.00 | 867.10 | 886.00 | 877.96 | 1,59,456 | 46.6% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- SUPRIYA
- BSE code
- 543434
- ISIN
- INE07RO01027
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.supriyalifescience.com
- CIN
- L51900MH2008PLC180452
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2008
- Registered office
- 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400063, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments